Recon: FDA declines to approve Ascendis’ hypoparathyroidism drug; Astellas to buy Iveric for $5.9B

[ad_1] Recon | 01 May 2023 |  By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US FDA advisory committee votes against plan…